Vitamin D and Calcium Supplement Attenuate Bone Loss among HIV-Infected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial

Background: Antiretroviral therapy (ART), especially with tenofovir disoproxil fumarate (TDF), has been associated with accelerated bone turnover and leads to significant bone loss. Objective: We aimed to determine the effect of vitamin D(2) and calcium on bone mineral density (BMD) in HIV-infected...

Descripción completa

Detalles Bibliográficos
Autores principales: Boontanondha, Patawee, Nimitphong, Hataikarn, Musikarat, Suchawadee, Ragkho, Aschara, Kiertiburanakul, Sasisopin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2020
Materias:
Current HIV Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516332/
https://www.ncbi.nlm.nih.gov/pubmed/31906840
http://dx.doi.org/10.2174/1570162X18666200106150806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516332/
https://www.ncbi.nlm.nih.gov/pubmed/31906840
http://dx.doi.org/10.2174/1570162X18666200106150806

Ejemplares similares